MEDICAL AFFAIRS
Abbott Diabetes Care
Congress Materials
Advanced Technologies & Treatments for Diabetes
2024 Congress
6 – 9 March, 2024 | Florence, Italy
Presentations and Materials
Poster
Initiating GLP-1 therapy in combination with FreeStyle Libre provides greater benefit compared to GLP-1 therapy alone.
ATTD 2024 Abstracts, Diabetes Technology & Therapeutics, 2024;26(2_suppl).
Eugene E. Wright, Gregory J. Roberts, Joyce S. Chuang, Yelena Nabutovsky, Naunihal Virdi, Eden Miller.
Poster
FreeStyle Libre improves HbA1c in people receiving GLP-1 therapy for type 2 diabetes.
ATTD 2024 Abstracts, Diabetes Technology & Therapeutics, 2024;26(2_suppl).
Eden Miller, Joyce S. Chuang, Gregory J. Roberts, Yelena Nabutovsky, Naunihal Virdi, Eugene E. Wright.
Poster
Using Freestyle Libre CGM with GLP-1 treatment is a cost-effective combination for people living with Type 2 diabetes.
ATTD 2024 Abstracts, Diabetes Technology & Therapeutics, 2024;26(2_suppl).
Eugene E Wright, Eden Miller, Anila Bindal, Yeesha Poon.
Presentation
Impact of continuous glucose monitoring on healthcare resource utilization among Medicaid beneficiaries with Type 2 diabetes treated with multiple daily injection therapy: Real-world insights from the US.
ATTD 2024 Abstracts, Diabetes Technology & Therapeutics, 2024;26(2_suppl).
Irl B. Hirsch, Bhavya Sree Burugapalli, Laura Brandner, Yeesha Poon, Marie Frazzitta, Lakshmi Godavarthi, Naunihal Virdi.
Presentation
Large individual variation and smaller racial group differences in red blood cell glucose uptake may contribute to discordance between HbA1c and average glucose.
ATTD 2024 Abstracts, Diabetes Technology & Therapeutics, 2024;26(2_suppl).
Joel D. Paprocki, Patrick Macdonald, Yongjin Xu, Alan Cheng, Timothy C. Dunn.
Presentation
Prospective use of personal glycation ratio improves racial differences in glycated hemoglobin assessment of average glucose.
ATTD 2024 Abstracts, Diabetes Technology & Therapeutics, 2024;26(2_suppl).
Richard M. Bergenstal, Yongjin Xu, Timothy C. Dunn, Ramzi A. Ajjan.
Poster
Glucose control in people with type 1 diabetes in Sweden after switching from real-time CGM to intermittently-scanned CGM.
ATTD 2024 Abstracts, Diabetes Technology & Therapeutics, 2024;26(2_suppl).
Jan Bolinder, Katarina Eeg-Olofsson, Tim Spelman, Erik Bülow, Mattias Kyhlstedt, Fleur Levrat-Guillen, David Nathanson.
Poster
Contributions of scan frequency and bolus frequency to time in range: Data from CGM and connected pens.
ATTD 2024 Abstracts, Diabetes Technology & Therapeutics, 2024;26(2_suppl).
Pratik Choudhary, Kalvin Kao, Farhan Quadri, Elemer Balogh and Jody Foster.
Presentation
Impact of continuous glucose monitoring on healthcare resource utilization among Medicaid beneficiaries with Type 2 diabetes treated with basal insulin.
ATTD 2024 Abstracts, Diabetes Technology & Therapeutics, 2024;26(2_suppl).
Irl B. Hirsch, Bhavya Sree Burugapalli, Laura Brandner, Yeesha Poon, Marie Frazzitta, Naunihal Virdi.
